EZH2 and colorectal carcinoma: Specifically, we took advantage of the possibility to further characterize a CRC cell line (HCT-shEZ-2) where EZH2 is permanently silenced and of a new compound able to specifically inhibit EZH2 methyltransferase activity, named GSK-343, as well as a compound able to disrupt the PRC2 complex, named DZNep.